Short answer
OCULAR THERAPEUTIX, INC (OCUL) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $11M (up 0.8% year over year) with net income of −$89M.
Q1 2026 key financials · XBRL
- Revenue
- $11M
- +0.8% YoY
- Net income
- −$89M
- −38.3% YoY
- Operating margin
- -865.5%
- EPS (diluted)
- −$0.40
- −5.3% YoY
Source: XBRL data from the OCULAR THERAPEUTIX, INC (OCUL) Q1 2026 10-Q on SEC EDGAR. USD.
OCULAR THERAPEUTIX, INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- DEXTENZA revenue $10.8M, up $0.2M or 1.9% YoY
- In-market sales approximately 42,000 units, up approximately 2,000 YoY
- Commercial outlook: continued 2026 revenue growth from HOPD sales efforts
- Headwind: slightly higher gross-to-net adjustments from increased OID
- R&D expenses expected to increase with continued product-candidate development
Risk Factors
- Newly disclosed executive trading arrangement: David Robinson adopted a Rule 10b5-1 sell-to-cover plan January 26, 2026
- Equity-sale exposure: covered RSU share volume indeterminable because it depends on vesting, stock price, and future grants
- Compliance risk: insider transactions must comply with federal securities laws prohibiting trading on material nonpublic information
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OCULAR THERAPEUTIX, INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.